Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN1201 in newly diagnosed high-risk multiple myeloma
NCT07114432Phase 1Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RN1201 in multiple myeloma (MM), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Incidence and severity of dose-limiting toxicities at 28 days and Incidence and severity of treatment-emergent adverse events at 24 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
RN1201
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07114432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114432.